Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

9 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(66.7%)
Phase 3
3(33.3%)
9Total
Phase 4(6)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06641440Phase 4Completed

Treatment With Prednisone of Women With RPL or RIF Positive to Antithyroid Antibodies and Embryotoxicity Test

Role: lead

NCT03421639Phase 4Active Not Recruiting

Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

Role: lead

NCT01712763Phase 3Completed

Degarelix in the Treatment of Endometriosis Recurrence

Role: lead

NCT01715974Phase 3Unknown

Use of GM-CSF Treatment in Recurrent Implantation Failure

Role: lead

NCT01718210Phase 4Completed

Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure

Role: lead

NCT01709942Phase 3Completed

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

Role: lead

NCT01779232Phase 4Completed

Danazol Treatment in Endometriosis Women Before IVF

Role: lead

NCT01769781Phase 4Completed

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Role: lead

NCT02651285Phase 4Unknown

Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF

Role: lead

All 9 trials loaded